609 related articles for article (PubMed ID: 8244583)
1. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
2. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
[TBL] [Abstract][Full Text] [Related]
3. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
4. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
Brooks SE; Korbut TT; Dupuis NP; Holden SA; Teicher BA
Cancer Chemother Pharmacol; 1995; 36(5):431-8. PubMed ID: 7634385
[TBL] [Abstract][Full Text] [Related]
6. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
7. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.
Lee KS; Kim HK; Moon HS; Hong YS; Kang JH; Kim DJ; Park JG
Korean J Intern Med; 1992 Jul; 7(2):111-7. PubMed ID: 1306072
[TBL] [Abstract][Full Text] [Related]
8. Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines.
Mans DR; Schuurhuis GJ; Treskes M; Lafleur MV; Retèl J; Pinedo HM; Lankelma J
Eur J Cancer; 1992; 28A(8-9):1447-52. PubMed ID: 1325177
[TBL] [Abstract][Full Text] [Related]
9. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
Xu BH; Gupta V; Singh SV
Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
[TBL] [Abstract][Full Text] [Related]
11. [Potentiation of cisplatin sensitivity of cisplatin-resistant human ovarian cancer cell lines by L-buthionine-S,R-sulfoximine].
Kudoh K; Kita T; Hirata J; Ishii K; Hiramatsu H; Kikuchi Y; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Jun; 46(6):525-32. PubMed ID: 8040625
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line.
Singh SV; Xu BH; Jani JP; Emerson EO; Backes MG; Rihn C; Scalamogna D; Stemmler N; Specht S; Blanock K
Int J Cancer; 1995 May; 61(3):431-6. PubMed ID: 7729958
[TBL] [Abstract][Full Text] [Related]
13. Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo.
Bier H
Acta Otolaryngol; 1991; 111(4):797-806. PubMed ID: 1950544
[TBL] [Abstract][Full Text] [Related]
14. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
15. Promotion of trans-platinum in vivo effects on renal heme and hemoprotein metabolism by D,L-buthionine-S,R-sulfoximine. Possible role of glutathione.
Mayer RD; Maines MD
Biochem Pharmacol; 1990 May; 39(10):1565-71. PubMed ID: 2337413
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
Chen G; Zeller WJ
Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
[TBL] [Abstract][Full Text] [Related]
17. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.
Meijer C; Mulder NH; Hospers GA; Uges DR; de Vries EG
Br J Cancer; 1990 Jul; 62(1):72-7. PubMed ID: 2390486
[TBL] [Abstract][Full Text] [Related]
18. Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line.
Pendyala L; Perez R; Weinstein A; Zdanowicz J; Creaven PJ
Cancer Chemother Pharmacol; 1997; 40(1):38-44. PubMed ID: 9137527
[TBL] [Abstract][Full Text] [Related]
19. Exogenous glutathione attenuates the antiproliferative effect of buthionine sulfoximine.
Kang YJ
Toxicology; 1994 Mar; 88(1-3):177-89. PubMed ID: 8160199
[TBL] [Abstract][Full Text] [Related]
20. Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factor-alpha mRNA down-regulation in tumor cell sensitization.
Mizutani Y; Yoshida O
Cancer; 1994 Feb; 73(3):730-7. PubMed ID: 8299097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
